Hereditary Testing Market– Statistics And Analysis & Forecast To 2026

Posted by Mrudula Anil Karmarkar on May 21st, 2021

The global hereditary testing market size is expected to reach USD 8.9 billion by 2026, expanding at a CAGR of 6.3% over the forecast period, according to a new report by Grand View Research, Inc. Key factors driving the market are declining cost of sequencing and availability of genetic tests at a lower price. Furthermore, the availability of niche and fragmented point-solutions across genomics value chain, namely sequencing, analytics, interpretation, aggregation, and marketplace, is anticipated to propel the market growth over the forecast period.

The most common concern for the governments of all Covid-19 hit nations is the excruciating need to screen for and test large numbers of patients for possible Sars-Cov-2 infection. As a result, most of them are facing major shortages in the supply for diagnostic kits to test for the virus. Diagnostics virology entities are under immense pressure to provide reliable testing kits, and there is a surge in demand for in-vitro or point-of-care testing capacities by labs across a large number of countries. The report will account for Covid19 as a key market contributor.

The advent of direct-to-consumer genetics is anticipated to play a major role in the genetic testing market by enabling individuals to carry out self-testing. This expands the role of genetic counselors, which further aids in understanding the importance of genetic tests and helps in the selection of appropriate tests. A growing number of registered genetic counselors is anticipated to boost the adoption of hereditary genetic tests in the coming years.

Technology developers are introducing advanced products to enhance the efficiency of genetic tests by diagnostic companies. For example, in June 2020, QIAGEN launched a new QIAseq Expanded Carrier Screening Panel, a novel Next-generation Sequencing (NGS) panel integrated with advanced bioinformatics solutions for rare and inherited diseases testing. Such ongoing developments in the market space are expected to boost revenue growth to a large extent in the coming years.

Furthermore, a consistent rise in demand for newborn screening has led to an increase in sales of DNA testing kits. For instance, in November 2020, the Division of Consolidated Laboratory Services (DCLS) of the Virginia Department of General Services screened 7,868 newborns for nearly 31 hereditary and metabolic disorders. Increasing penetration of newborn screening across the globe is further aiding in revenue growth.

Hereditary Testing Market Report Highlights

  • A substantial number of CLIA-certified laboratories perform tests to determine whether an individual carries an inherited mutated gene that can cause cancer. This has led to increased hereditary testing market share of hereditary testing for cancer in 2020
  • Breast cancer testing segment has dominated the hereditary cancer testing market owing to its high penetration and increased inheritability
  • On the other hand, most of the cases of cervical cancer are non-hereditary, resulting in the lowest revenue share of this segment
  • Emergence of high-throughput sequencing has resulted in commercial availability of a significant number of sequencing assays for cardiomyopathies, thereby driving the cardiac diseases segment
  • Non-invasive Prenatal Testing (NIPT) and newborn genetic screening continue to witness lucrative growth due to increased adoption across the globe
  • Moreover, the newborn screening program has been made mandatory in several regions and countries, resulting in large share of these test types among the hereditary non-cancer testing segment
  • Europe and North America collectively accounted for nearly 70% of the revenue generated in 2020 owing to assisted reproductive technology space coupled with high penetration of newborn genetic screening
  • Myriad Genetics, Inc.; Quest Diagnostics Incorporated; Invitae Corporation; Illumina, Inc.; and Natera, Inc. are some of the major key players operating in the marketplace
  • These companies are engaged in securing regulatory approval in the emerging countries to expand their business footprint
  • A substantial number of diagnostic companies have collaborated with technology developers to obtain technology license and deliver high value services to their customers.

Reforms in genetic testing guidelines have led to inclusion of multigene panel testing for hereditary cancer into clinical practice. The National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast, ovarian, and colorectal cancers offers information on some of the cancer risk factors and management recommendations for single and multiple gene panels.

Gradual developments in the distribution model is likely to benefit the genetic testing market. Technology providers are playing a crucial role in market growth by improving their distribution service and increasing the efficiency of technology. Companies are using a cloud-based distribution model to make bioinformatics technology available for use by other laboratories. As of March 2020, around 14 licensees were using Constellation software commercially for the marketing of Non-invasive Prenatal Testing (NIPT) products.

Although these hereditary tests have huge advantages over conventional tests, several industry experts cited the cost and security concerns faced by consumers pertaining to the test. Moreover, the lack of effective regulation of the tests is another key area that demands focused efforts. Despite these challenges, the genetic testing market is constantly expanding owing to the advantages of these innovative tests along with improved healthcare outcomes.

Have a Query? Ask Our Expert:

Understanding the role of genetic mutation in disease occurrence has significantly accelerated the R&D in this market. Various retrospective studies are being carried out to understand the role of inherited mutations in disease pathology, which has led to key diagnostic developers, such as Quest Diagnostics, enter the market. Continuous authorizations and approvals of genetic tests by the government is expected to propel the organic revenue growth of operating companies.

Some of the key players engaged in offering services and products in this market are Myriad Genetics, Inc.; Invitae Corporation; Illumina, Inc.; Natera, Inc.; Laboratory Corporation of America Holdings; F. Hoffmann-La Roche Ltd; Quest Diagnostics Incorporated; CooperSurgical, Inc.; Agilent Technologies, Inc.; Thermo Fisher Scientific, Inc.; Twist Bioscience; Sophia Genetics; Fulgent Genetic, Inc.; Medgenome; and CENTOGENE N.V.

Furthermore, the expanding product portfolio is indicative of growing competition in the market. Each company is making focused efforts to offer products with a competitive advantage. For example, cross-selling efforts by Natera helped the company witness lucrative revenue generation over the past years. The company promotes collective use of Horizon and Panorama products for women who have not undergone carrier screening tests in their first trimester.

Grand View Research has segmented the global hereditary testing market on the basis of disease type:

Hereditary Testing Disease Type Outlook (Revenue, USD Million, 2015 - 2026)

  • Hereditary Cancer Testing
    • Lung Cancer
    • Breast Cancer
    • Colorectal Cancer
    • Cervical Cancer
    • Ovarian Cancer
    • Prostate Cancer
    • Stomach/Gastric Cancer
    • Melanoma
    • Sarcoma
    • Uterine Cancer
    • Pancreatic Cancer
    • Others
  • Hereditary Non-cancer Testing
    • Genetic Tests
      • Cardiac Diseases
      • Rare Diseases
      • Other Diseases
    • Newborn Genetic Screening
    • Preimplantation Genetic Diagnosis & Screening
    • Non-invasive Prenatal Testing (NIPT) & Carrier Screening Tests

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For More

Like it? Share it!

Mrudula Anil Karmarkar

About the Author

Mrudula Anil Karmarkar
Joined: July 2nd, 2020
Articles Posted: 883

More by this author